KR102891741B1 - 아데노신 수용체 길항제로서의 티아졸로피리딘 유도체 - Google Patents
아데노신 수용체 길항제로서의 티아졸로피리딘 유도체Info
- Publication number
- KR102891741B1 KR102891741B1 KR1020217026069A KR20217026069A KR102891741B1 KR 102891741 B1 KR102891741 B1 KR 102891741B1 KR 1020217026069 A KR1020217026069 A KR 1020217026069A KR 20217026069 A KR20217026069 A KR 20217026069A KR 102891741 B1 KR102891741 B1 KR 102891741B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- compounds
- present
- group
- spp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19152961 | 2019-01-22 | ||
| EP19152961.9 | 2019-01-22 | ||
| PCT/EP2020/051347 WO2020152132A1 (en) | 2019-01-22 | 2020-01-21 | Thiazolopyridine derivatives as adenosine receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210116572A KR20210116572A (ko) | 2021-09-27 |
| KR102891741B1 true KR102891741B1 (ko) | 2025-11-26 |
Family
ID=65199346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217026069A Active KR102891741B1 (ko) | 2019-01-22 | 2020-01-21 | 아데노신 수용체 길항제로서의 티아졸로피리딘 유도체 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12344623B2 (https=) |
| EP (1) | EP3914600B1 (https=) |
| JP (1) | JP7600119B2 (https=) |
| KR (1) | KR102891741B1 (https=) |
| CN (1) | CN113939520B (https=) |
| AR (1) | AR117844A1 (https=) |
| AU (1) | AU2020211697B2 (https=) |
| BR (1) | BR112021014406A2 (https=) |
| CA (1) | CA3127284A1 (https=) |
| DK (1) | DK3914600T3 (https=) |
| ES (1) | ES2992081T3 (https=) |
| FI (1) | FI3914600T3 (https=) |
| HR (1) | HRP20241385T1 (https=) |
| HU (1) | HUE068968T2 (https=) |
| IL (1) | IL285024A (https=) |
| LT (1) | LT3914600T (https=) |
| MX (1) | MX2021008510A (https=) |
| PL (1) | PL3914600T3 (https=) |
| PT (1) | PT3914600T (https=) |
| RS (1) | RS66038B1 (https=) |
| SG (1) | SG11202107858WA (https=) |
| SI (1) | SI3914600T1 (https=) |
| WO (1) | WO2020152132A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022258622A1 (en) | 2021-06-07 | 2022-12-15 | Ares Trading S.A. | Combination treatment of cancer |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| KR20250048043A (ko) | 2022-08-02 | 2025-04-07 | 메르크 파텐트 게엠베하 | (S)-7-옥사-2-아자-스피로[4.5]데칸-2-카르복실산 [7-(3,6-디히드로-2H-피란-4-일)-4-메톡시-티아졸로[4,5-c]피리딘-2-일]-아미드의 신규의 결정질 형태 및 이의 공-결정 형태 |
| CN116217511B (zh) * | 2023-03-22 | 2024-04-19 | 沈阳药科大学 | 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125828A (en) | 1972-08-04 | 1978-11-14 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| US4207554A (en) | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| AU1688599A (en) | 1998-01-05 | 1999-07-26 | Eisai Co. Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US6841549B1 (en) | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| AU8181701A (en) * | 2000-06-21 | 2002-01-02 | Hoffmann La Roche | Benzothiazole derivatives |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| US6734179B2 (en) * | 2001-12-12 | 2004-05-11 | Hoffmann-La Roche Inc. | Benzothiazoles |
| EP1465634B1 (en) | 2001-12-12 | 2014-10-22 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | Methods for using adenosine receptor inhibitors to enhance immune response and inflammation |
| EP1618108A2 (en) | 2003-04-09 | 2006-01-25 | Biogen Idec MA Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists |
| JP4444290B2 (ja) | 2003-05-19 | 2010-03-31 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのベンゾチアゾール誘導体 |
| BRPI0414266A (pt) * | 2003-09-19 | 2006-11-07 | Hoffmann La Roche | derivados de tiazolopiridina como ligandos receptores da adenosina |
| US7054288B2 (en) * | 2004-02-13 | 2006-05-30 | Interdigital Technology Corporation | Method and apparatus for providing fast detection of a high speed shared control channel |
| DE102004008908A1 (de) * | 2004-02-24 | 2005-09-08 | Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH | Ansteuerschaltung für Wandler |
| FR2867354A1 (fr) * | 2004-03-09 | 2005-09-16 | Joseph Vaillant | Ferrure mecanique pour sabot, notamment pour cheval de sport |
| CN1989139B (zh) | 2004-07-22 | 2010-05-12 | 弗·哈夫曼-拉罗切有限公司 | 苯并噻唑衍生物 |
| WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| US11220492B2 (en) * | 2017-05-17 | 2022-01-11 | Arcus Biosciences, Inc. | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
| RS64035B1 (sr) * | 2017-08-01 | 2023-04-28 | Merck Patent Gmbh | Derivati tiazolopiridina kao antagonisti receptora adenozina |
-
2020
- 2020-01-20 AR ARP200100134A patent/AR117844A1/es unknown
- 2020-01-21 BR BR112021014406A patent/BR112021014406A2/pt unknown
- 2020-01-21 RS RS20241147A patent/RS66038B1/sr unknown
- 2020-01-21 MX MX2021008510A patent/MX2021008510A/es unknown
- 2020-01-21 PL PL20700918.4T patent/PL3914600T3/pl unknown
- 2020-01-21 US US17/424,568 patent/US12344623B2/en active Active
- 2020-01-21 DK DK20700918.4T patent/DK3914600T3/da active
- 2020-01-21 AU AU2020211697A patent/AU2020211697B2/en active Active
- 2020-01-21 JP JP2021542335A patent/JP7600119B2/ja active Active
- 2020-01-21 SI SI202030510T patent/SI3914600T1/sl unknown
- 2020-01-21 ES ES20700918T patent/ES2992081T3/es active Active
- 2020-01-21 CA CA3127284A patent/CA3127284A1/en active Pending
- 2020-01-21 WO PCT/EP2020/051347 patent/WO2020152132A1/en not_active Ceased
- 2020-01-21 PT PT207009184T patent/PT3914600T/pt unknown
- 2020-01-21 HU HUE20700918A patent/HUE068968T2/hu unknown
- 2020-01-21 EP EP20700918.4A patent/EP3914600B1/en active Active
- 2020-01-21 HR HRP20241385TT patent/HRP20241385T1/hr unknown
- 2020-01-21 SG SG11202107858WA patent/SG11202107858WA/en unknown
- 2020-01-21 FI FIEP20700918.4T patent/FI3914600T3/fi active
- 2020-01-21 CN CN202080010474.8A patent/CN113939520B/zh active Active
- 2020-01-21 KR KR1020217026069A patent/KR102891741B1/ko active Active
- 2020-01-21 LT LTEPPCT/EP2020/051347T patent/LT3914600T/lt unknown
-
2021
- 2021-07-21 IL IL285024A patent/IL285024A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3914600T3 (da) | 2024-10-07 |
| KR20210116572A (ko) | 2021-09-27 |
| IL285024A (en) | 2021-09-30 |
| SI3914600T1 (sl) | 2025-03-31 |
| ES2992081T3 (es) | 2024-12-09 |
| LT3914600T (lt) | 2024-12-27 |
| RS66038B1 (sr) | 2024-11-29 |
| CA3127284A1 (en) | 2020-07-30 |
| CN113939520A (zh) | 2022-01-14 |
| MX2021008510A (es) | 2021-09-21 |
| US20220119412A1 (en) | 2022-04-21 |
| JP7600119B2 (ja) | 2024-12-16 |
| CN113939520B (zh) | 2024-11-22 |
| AU2020211697A1 (en) | 2021-09-09 |
| WO2020152132A1 (en) | 2020-07-30 |
| HUE068968T2 (hu) | 2025-02-28 |
| EP3914600B1 (en) | 2024-08-07 |
| PL3914600T3 (pl) | 2024-12-23 |
| EP3914600A1 (en) | 2021-12-01 |
| JP2022524914A (ja) | 2022-05-11 |
| FI3914600T3 (fi) | 2024-10-31 |
| SG11202107858WA (en) | 2021-08-30 |
| US12344623B2 (en) | 2025-07-01 |
| AU2020211697B2 (en) | 2025-08-14 |
| PT3914600T (pt) | 2024-10-04 |
| BR112021014406A2 (pt) | 2021-12-07 |
| AR117844A1 (es) | 2021-09-01 |
| HRP20241385T1 (hr) | 2024-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102891741B1 (ko) | 아데노신 수용체 길항제로서의 티아졸로피리딘 유도체 | |
| CN110997662B (zh) | 作为腺苷受体拮抗剂的苯并咪唑衍生物 | |
| JP7287951B2 (ja) | アデノシン受容体アンタゴニストとしてのキノキサリン誘導体 | |
| TWI850199B (zh) | 做為腺苷受體拮抗劑之噻唑并吡啶衍生物 | |
| US20250049814A1 (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| RU2810114C2 (ru) | Тиазолопиридиновые производные в качестве антагонистов аденозиновых рецепторов | |
| RU2781429C2 (ru) | Бензимидазольные производные в качестве антагонистов аденозиновых рецепторов | |
| RU2790011C2 (ru) | Тиазолопиридиновые производные в качестве антагонистов аденозиновых рецепторов | |
| RU2791168C1 (ru) | Хиноксалиновые производные в качестве антагонистов аденозиновых рецепторов | |
| BR112020001978B1 (pt) | Derivados de tiazolopiridina como antagonistas de receptor de adenosina, seu processo de preparação e seu uso, preparação farmacêutica e seu processo de preparação, e kit | |
| AU2023375996A1 (en) | Substituted bi-and tricyclic hset inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |